In this review:
At ESMO this year, presentations continued the trend of molecular matching, reinforcing the need to subclassify tumour types by their characteristic genetic alterations. It was particularly exciting to see the increasing focus on rare cancers, with molecular subtyping, and successful trials in tumours such as cholangiocarcinoma and cervical cancer where we have had only limited success with chemotherapy. Similarly, there are now also trials in rare cancers that are more likely to succeed by selecting the subgroup of patients most likely to benefit from therapy, rather than the days of administering the same drug to all patients with a tumour type and hoping some will benefit.
Please login below to download this issue (PDF)